Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TPBGL antisense RNA 1 (TPBGL-AS1) is a long non-coding RNA transcript mapped in the NCBI Gene database (Accession: 105369388). There is no available evidence for its physiological function, role as a drug target, aliases, or involvement in disease. In the context of functional studies or drug development, antisense lncRNAs are recognized for their ability to regulate gene expression by forming RNA duplexes with sense mRNAs, recruiting chromatin-modifying proteins, and acting as competing endogenous RNAs in disease (not specifically for TPBGL-AS1). Current evidence suggests TPBGL-AS1 is a catalogued non-coding RNA gene, but there is insufficient data to classify it as a drug or biomarker target, or assign aliases and functional roles. The information about this molecule is sparse, so any structured annotation will be limited.
None reported for TPBGL-AS1; antisense lncRNAs can modulate gene expression through chromatin modification, promoter competition, or as competing endogenous RNAs (ceRNA)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TPBGL antisense RNA 1 (TPBGL-AS1).